Prime Medicine (PRME) News Today $3.34 -0.25 (-6.95%) (As of 11/15/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Wedbush Estimates Prime Medicine FY2024 EarningsNovember 17 at 1:45 AM | americanbankingnews.comPrime Medicine, Inc. (NYSE:PRME) Given Consensus Recommendation of "Moderate Buy" by BrokeragesShares of Prime Medicine, Inc. (NYSE:PRME - Get Free Report) have earned an average rating of "Moderate Buy" from the nine analysts that are presently covering the company, MarketBeat reports. One investment analyst has rated the stock with a hold recommendation and eight have assigned a buy recoNovember 16 at 3:40 AM | marketbeat.comPrime Medicine, Inc. (PRME) Gets a Hold from Morgan StanleyNovember 15 at 5:17 PM | markets.businessinsider.comFY2024 EPS Estimate for Prime Medicine Decreased by AnalystPrime Medicine, Inc. (NYSE:PRME - Free Report) - Equities research analysts at HC Wainwright reduced their FY2024 earnings estimates for Prime Medicine in a research note issued on Wednesday, November 13th. HC Wainwright analyst A. He now expects that the company will earn ($1.69) per share for tNovember 15 at 6:52 AM | marketbeat.comWedbush Forecasts Prime Medicine FY2024 EarningsPrime Medicine, Inc. (NYSE:PRME - Free Report) - Equities research analysts at Wedbush issued their FY2024 earnings per share estimates for Prime Medicine in a research note issued on Tuesday, November 12th. Wedbush analyst D. Nierengarten forecasts that the company will post earnings of ($1.66)November 15 at 6:52 AM | marketbeat.comPrime Medicine Reports Q3 2024 Financial ProgressNovember 14 at 9:48 AM | markets.businessinsider.comIs Prime Medicine (NASDAQ:PRME) In A Good Position To Deliver On Growth Plans?November 14 at 9:48 AM | finance.yahoo.comPrime Medicine, Inc.: Strategic Initiatives and Promising Developments Drive Buy RatingNovember 14 at 4:47 AM | markets.businessinsider.comPrime Medicine, Inc. Receives Buy Rating from Arthur He CFA: Strategic Partnerships and Pipeline Focus Drive Promising Future ProspectsNovember 14 at 4:47 AM | markets.businessinsider.comPrime Medicine's (PRME) "Buy" Rating Reiterated at HC WainwrightHC Wainwright reaffirmed a "buy" rating and set a $10.00 price target on shares of Prime Medicine in a research report on Wednesday.November 13, 2024 | marketbeat.comPrime Medicine, Inc. (PRME) Receives a Buy from TD CowenNovember 13, 2024 | markets.businessinsider.comARK Investment Management LLC Reduces Holdings in Prime Medicine, Inc. (NYSE:PRME)ARK Investment Management LLC lowered its stake in shares of Prime Medicine, Inc. (NYSE:PRME - Free Report) by 7.6% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 5,660,719 shares of the company's stock after sellingNovember 8, 2024 | marketbeat.comPrime Medicine to Participate in Upcoming Investor ConferencesNovember 6, 2024 | globenewswire.com12 High-Growth Stocks That Could Deliver Parabolic ReturnsOctober 28, 2024 | fool.comPrime Medicine’s Gene Editing Breakthrough: High Efficiency and Therapeutic Potential in Liver-Specific DiseasesOctober 26, 2024 | markets.businessinsider.comPrime Medicine’s Promising Gene Editing Advancements Justify Buy RatingOctober 26, 2024 | markets.businessinsider.comPrime Medicine treatment of retinal dystrophy granted orphan designationOctober 26, 2024 | markets.businessinsider.comPrime Medicine Advances Gene Editing for Liver DiseasesOctober 25, 2024 | markets.businessinsider.comPrime Medicine presents data from multiple studies showcasing LNP platformOctober 25, 2024 | markets.businessinsider.comPrime Medicine (NYSE:PRME) Receives Buy Rating from HC WainwrightHC Wainwright reiterated a "buy" rating and issued a $10.00 price objective on shares of Prime Medicine in a report on Friday.October 25, 2024 | marketbeat.comPrime Medicine Presents In Vivo Proof-of-Concept Data Highlighting Interim Preclinical Advances in its Wilson's Disease Program and the Broad Potential of its Universal Liver-Targeted LNP at ESGCT 31st Annual CongressOctober 24, 2024 | globenewswire.comPrime Medicine (NYSE:PRME) Shares Down 4.6% - Should You Sell?Prime Medicine (NYSE:PRME) Stock Price Down 4.6% - Should You Sell?October 22, 2024 | marketbeat.comPrime Medicine (NYSE:PRME) Stock Price Up 15% - What's Next?Prime Medicine (NYSE:PRME) Trading Up 15% - Time to Buy?October 18, 2024 | marketbeat.comWhy I Keep Buying These 14 Incredible Growth StocksOctober 16, 2024 | fool.comPrime Medicine to Highlight New Preclinical Data, Including In Vivo Data in Wilson’s Disease, at Upcoming Scientific MeetingsOctober 15, 2024 | finance.yahoo.comPrime Medicine to Highlight New Preclinical Data, Including In Vivo Data in Wilson's Disease, at Upcoming Scientific MeetingsOctober 15, 2024 | globenewswire.comPrime Medicine, Inc. (PRME) Receives a Hold from Morgan StanleyOctober 12, 2024 | markets.businessinsider.comMillennium Management LLC Has $6.84 Million Stock Holdings in Prime Medicine, Inc. (NYSE:PRME)Millennium Management LLC grew its holdings in Prime Medicine, Inc. (NYSE:PRME - Free Report) by 205.7% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,330,927 shares of the company's stock after purchasing an adOctober 11, 2024 | marketbeat.comPrime Medicine’s Strategic Alliances and Growth Potential Affirm Buy RatingOctober 2, 2024 | markets.businessinsider.comBuy Rating Affirmed for Prime Medicine on Strategic Partnerships and Technology Platform PotentialOctober 2, 2024 | markets.businessinsider.comGot $100? Consider Buying These 2 Penny Stocks in OctoberOctober 1, 2024 | 247wallst.comBuy Rating Reaffirmed for Prime Medicine on Strong Cash Position and Promising Technology PlatformsOctober 1, 2024 | markets.businessinsider.comBristol, Prime Medicine in deal to develop T-cell therapiesOctober 1, 2024 | seekingalpha.comPrime Medicine, Inc. (PRME) Gets a Hold from Stifel NicolausOctober 1, 2024 | markets.businessinsider.comWhy Prime Medicine Stock Soared Nearly 12% Higher on MondaySeptember 30, 2024 | fool.comCrude Oil Moves Higher; Prime Medicine Shares Spike HigherSeptember 30, 2024 | benzinga.comPrime Medicine Unveils Strategically Focused PipelineSeptember 30, 2024 | globenewswire.comWestwood Holdings Group Inc. Boosts Stock Holdings in Prime Medicine, Inc. (NYSE:PRME)Westwood Holdings Group Inc. grew its position in shares of Prime Medicine, Inc. (NYSE:PRME - Free Report) by 125.0% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 358,580 shares of the company's stockSeptember 23, 2024 | marketbeat.comPrime Healthcare Nationally Recognized for Quality in Stroke and Heart Failure CareSeptember 18, 2024 | businesswire.comPrime Medicine's Promising Pipeline: PM359 And Cash Burn ConcernsSeptember 4, 2024 | seekingalpha.comPrime Medicine (NYSE:PRME) Shares Gap Up to $4.28Prime Medicine (NYSE:PRME) Shares Gap Up to $4.28September 3, 2024 | marketbeat.comPrime Medicine, Inc. (NYSE:PRME) Given Consensus Rating of "Moderate Buy" by BrokeragesShares of Prime Medicine, Inc. (NYSE:PRME - Get Free Report) have been assigned an average rating of "Moderate Buy" from the eleven ratings firms that are covering the stock, Marketbeat reports. One investment analyst has rated the stock with a hold rating and ten have given a buy rating to the cSeptember 2, 2024 | marketbeat.comPrime Medicine (NYSE:PRME) Stock Price Down 4.9%Prime Medicine (NYSE:PRME) Trading Down 4.9%August 27, 2024 | marketbeat.comPrime Medicine (NYSE:PRME) Shares Up 5.4%Prime Medicine (NYSE:PRME) Stock Price Up 5.4%August 26, 2024 | marketbeat.comSumitomo Mitsui Trust Holdings Inc. Sells 126,278 Shares of Prime Medicine, Inc. (NYSE:PRME)Sumitomo Mitsui Trust Holdings Inc. cut its holdings in shares of Prime Medicine, Inc. (NYSE:PRME - Free Report) by 3.8% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 3,238,385 shares ofAugust 21, 2024 | marketbeat.comPrime Medicine (NYSE:PRME) Trading 6.1% Higher Prime Medicine (NYSE:PRME) Shares Up 6.1%August 19, 2024 | marketbeat.comPrime Medicine (NYSE:PRME) Shares Down 3.9% Prime Medicine (NYSE:PRME) Trading Down 3.9%August 16, 2024 | marketbeat.comFY2024 EPS Estimates for Prime Medicine, Inc. Lowered by Chardan Capital (NYSE:PRME)Prime Medicine, Inc. (NYSE:PRME - Free Report) - Analysts at Chardan Capital reduced their FY2024 earnings estimates for shares of Prime Medicine in a research report issued to clients and investors on Monday, August 12th. Chardan Capital analyst G. Livshits now anticipates that the company willAugust 15, 2024 | marketbeat.comPrime Medicine (NYSE:PRME) Hits New 1-Year Low at $3.99Prime Medicine (NYSE:PRME) Reaches New 1-Year Low at $3.99August 12, 2024 | marketbeat.comPrime Medicine, Inc. (NYSE:PRME) Expected to Earn Q3 2024 Earnings of ($0.46) Per SharePrime Medicine, Inc. (NYSE:PRME - Free Report) - Wedbush cut their Q3 2024 EPS estimates for shares of Prime Medicine in a report released on Thursday, August 8th. Wedbush analyst D. Nierengarten now anticipates that the company will post earnings per share of ($0.46) for the quarter, down from tAugust 12, 2024 | marketbeat.com Get Prime Medicine News Delivered to You Automatically Sign up to receive the latest news and ratings for PRME and its competitors with MarketBeat's FREE daily newsletter. Email Address [Urgent] Starlink Set For The Largest IPO In History? (Ad)He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again with Tesla… which is up more than 19,500% since 2010. For perspective, that turns $100 invested into almost $20,000! And now, Elon could be set to do it for the third and final time… with what might be his biggest breakthrough yet. And for the first time ever, you have the rare chance to profit BEFORE the upcoming IPO. Click here now for the urgent details on this hidden play. PRME Media Mentions By Week PRME Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PRME News Sentiment▼0.190.55▲Average Medical News Sentiment PRME News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PRME Articles This Week▼173▲PRME Articles Average Week Get Prime Medicine News Delivered to You Automatically Sign up to receive the latest news and ratings for PRME and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Neumora Therapeutics News Recursion Pharmaceuticals News Tarsus Pharmaceuticals News Immunocore News BioCryst Pharmaceuticals News Novavax News Mesoblast News Vir Biotechnology News Immatics News LENZ Therapeutics News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NYSE:PRME) was last updated on 11/17/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Prime Medicine, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Prime Medicine With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
